Beijing Bohui Innovation Biotechnology Group (300318) News

Bohui Innovation: First Quarter Report for 2026

SZSIApr 28 00:00 · Announcements

Bohui Innovation (300318.SZ) reported a net loss of 91.9232 million yuan in 2025.

Gelonghui, April 25th ┃ Bohui Innovation (300318.SZ) released its 2025 annual report, showing that the company achieved a total operating revenue of 825 million yuan for the full year, representing a year-on-year decline of 3.18%; net profit attributable to shareholders was -91.9232 million yuan; non-recurring net profit attributable to shareholders was -66.7938 million yuan.

Gelonghui FinanceApr 25 12:27

Bohui Innovation: Summary of the 2025 Annual Report

SZSIApr 25 00:00 · Announcements

Bohui Innovation: 2025 Annual Report

SZSIApr 25 00:00 · Announcements

Bohui Innovation (300318.SZ): Signs 'Equity Entrustment Agreement' with Controlling Shareholder

Gelonghui, February 4th: Bohui Innovation (300318.SZ) announced that the company's controlling shareholder and Mr. Du Jiangtao, a shareholder of Bohui Biopharmaceuticals (Hebei) Co., Ltd. (hereinafter referred to as "Hebei Bohui"), signed an Equity Transfer Agreement with Beijing Tongying Investment Group Co., Ltd. (hereinafter referred to as "Tongying Group") to acquire 14.7001% of Hebei Bohui’s shares held by Tongying Group. To safeguard the independence of the company and avoid actual or potential competition between the controlling shareholder and the company, Mr. Du Jiangtao, the company's controlling shareholder, plans to sign an Equity Entrustment Agreement with the company, intending to entrust the acquired shares of Hebei Bohui.

Gelonghui FinanceFeb 4 17:42

Nipah Virus Draws Attention as Diagnostic Kits Race Ahead, but Barriers Remain for Antiviral Drug Development

①The recent cluster outbreak of the Nipah virus in India has been relatively small-scale, with no reported cases of regional spillover so far; ②The related market movements in this instance are essentially typical event-driven speculative trading, with only a few areas having a short-term basis for earnings realization.

cls.cnJan 30 20:46

High fatality rate! Nipah virus outbreak in India, Chinese team discovers effective drug

Major Breakthrough in China's Scientific Research

Gelonghui FinanceJan 27 15:00

Bohui Innovation: 2025 Annual Performance Forecast

SZSIJan 23 00:00 · Announcements

Bohui Innovation (300318.SZ): Estimated net loss of 59 million to 117 million yuan in 2025

Gelonghui, January 22nd - Bohui Innovation (300318.SZ) announced an estimated net loss of RMB 117 million to RMB 59 million for 2025, and a non-net loss of RMB 87 million to RMB 44 million. 1. During the reporting period, the company's operating revenue decreased year-over-year, and the net profit attributable to shareholders of the listed company also declined year-over-year; the company’s net profit is expected to be in a loss: (1) The company’s operating revenue slightly declined during the reporting period. Among this, the in-vitro diagnostic business was significantly affected by the full implementation of the centralized procurement policy, resulting in a notable year-over-year decrease in the selling price of the company’s HPV products. Meanwhile, the terminal market demand for some testing products has fallen compared to the same period last year.

Gelonghui FinanceJan 22 16:45

Express News | Bohui Innovation: Controlled subsidiary jointly receives clinical trial approval notice for freeze-dried human rabies vaccine

BreakingsJan 13 18:24

Bohui Innovation (300318.SZ): Intravenous Human Immunoglobulin Receives Approval for Clinical Trial

Gelonghui, December 23rd ┃ Bo Hui Innovation (300318.SZ) announced that its holding subsidiary, Guangdong Weilun Biopharmaceutical Co., Ltd. (“Guangdong Weilun”), has received the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration for its application of intravenous human immunoglobulin, and has been approved to commence clinical trials. Indications: 1. Primary immunoglobulin deficiency diseases, such as X-linked agammaglobulinemia, common variable immunodeficiency, and immunoglobulin G subclass deficiency. 2. Secondary immunoglobulin deficiency diseases, such as severe infections and neonatal sepsis. 3. Autoimmune diseases, such as primary...

Gelonghui FinanceDec 23, 2025 16:12

Express News | Bohui Innovation: Controlling subsidiary receives drug registration certificate for human coagulation factor VIII

BreakingsDec 23, 2025 16:09

Blood Products Industry Enters Deep-Water Zone of Cyclical Adjustment as the 'Easy Profit' Bonanza Ends | Industry Watch

①Amid the convergence of multiple challenges, including tightened medical insurance cost controls, the advancement of centralized procurement policies, and increased uncertainty on the demand side, the industry is undergoing 'growing pains' and entering a new phase of cyclical adjustment and transition. ②In order to capture a larger market share, companies have been compelled to adopt a 'volume-for-price' strategy, where sales growth has been accompanied by price reductions, directly leading to revenue growth without a corresponding increase in profitability.

cls.cnDec 18, 2025 09:10

Express News | Bohui Innovation: The company is currently operating normally, with no significant matters that should be disclosed but have not been disclosed.

BreakingsNov 13, 2025 17:06

Bohui Innovation Biotechnology JV Gets Clinical Trial Approval for Hib Vaccine

MT NewswiresNov 12, 2025 19:49

Express News | The concept of influenza remains highly active, with TEYI Pharmaceutical achieving a two-day consecutive limit-up.

BreakingsNov 12, 2025 09:43

Express News | Bohui Innovation: Controlling subsidiary jointly receives clinical trial approval notice for freeze-dried Haemophilus influenzae type b conjugate vaccine

BreakingsNov 11, 2025 17:26

Bohui Innovation: Report for the third quarter of 2025

SZSIOct 30, 2025 00:00 · Announcements

Bohui Innovation: 2025 Semi-Annual Report Summary

SZSIAug 28, 2025 00:00 · Announcements

Bohui Innovation: 2025 Semi-Annual Report

SZSIAug 28, 2025 00:00 · Announcements